- Home
- ANIX vs HURA Comparison
ANIX vs HURA Comparison
Compare ANIX & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- HURA
- Stock Information
- Founded
- ANIX 1982
- HURA 2009
- Country
- ANIX United States
- HURA United States
- Employees
- ANIX N/A
- HURA N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- HURA
- Sector
- ANIX Health Care
- HURA
- Exchange
- ANIX Nasdaq
- HURA Nasdaq
- Market Cap
- ANIX 84.7M
- HURA 96.5M
- IPO Year
- ANIX 1987
- HURA N/A
- Fundamental
- Price
- ANIX $2.38
- HURA $3.91
- Analyst Decision
- ANIX Strong Buy
- HURA Strong Buy
- Analyst Count
- ANIX 3
- HURA 2
- Target Price
- ANIX $9.00
- HURA $11.50
- AVG Volume (30 Days)
- ANIX 69.9K
- HURA 309.8K
- Earning Date
- ANIX 06-03-2025
- HURA 05-15-2025
- Dividend Yield
- ANIX N/A
- HURA N/A
- EPS Growth
- ANIX N/A
- HURA N/A
- EPS
- ANIX N/A
- HURA N/A
- Revenue
- ANIX N/A
- HURA N/A
- Revenue This Year
- ANIX N/A
- HURA N/A
- Revenue Next Year
- ANIX N/A
- HURA $69.15
- P/E Ratio
- ANIX N/A
- HURA N/A
- Revenue Growth
- ANIX N/A
- HURA N/A
- 52 Week Low
- ANIX $2.07
- HURA $1.80
- 52 Week High
- ANIX $4.20
- HURA $14.60
- Technical
- Relative Strength Index (RSI)
- ANIX 28.31
- HURA N/A
- Support Level
- ANIX $2.67
- HURA N/A
- Resistance Level
- ANIX $2.97
- HURA N/A
- Average True Range (ATR)
- ANIX 0.21
- HURA 0.00
- MACD
- ANIX -0.07
- HURA 0.00
- Stochastic Oscillator
- ANIX 4.95
- HURA 0.00
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.